CapsoVision (NASDAQ:CV) Shares Down 3.1% – Here’s What Happened

by · The Cerbat Gem

Shares of CapsoVision, Inc. (NASDAQ:CV – Get Free Report) were down 3.1% during trading on Thursday . The company traded as low as $11.58 and last traded at $11.77. Approximately 12,597 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 163,405 shares. The stock had previously closed at $12.15.

Analyst Ratings Changes

CV has been the topic of a number of research analyst reports. Roth Capital set a $7.00 price target on shares of CapsoVision in a research note on Tuesday, November 4th. Zacks Research raised CapsoVision to a “hold” rating in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of CapsoVision in a report on Monday. Finally, Benchmark reiterated a “speculative buy” rating on shares of CapsoVision in a research report on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $6.00.

Check Out Our Latest Research Report on CV

CapsoVision Price Performance

The business’s fifty day moving average is $6.19.

CapsoVision (NASDAQ:CV – Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The business had revenue of $3.54 million during the quarter.

Institutional Investors Weigh In On CapsoVision

An institutional investor recently bought a new position in CapsoVision stock. Citadel Advisors LLC acquired a new position in CapsoVision, Inc. (NASDAQ:CV – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 23,735 shares of the company’s stock, valued at approximately $115,000. Citadel Advisors LLC owned about 0.05% of CapsoVision at the end of the most recent quarter.

CapsoVision Company Profile

(Get Free Report)

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.

See Also